Sonoma Pharmaceuticals Investor Presentation — June 2018

Document content

NASDAQ: SNOASONOMA PHARMACEUTICALSFOURTH QUARTER & FY2018 RESULTSJune 13, 2018

2Welcome / IntroductionMarch 31, 2018 HighlightsFinancial Review Q+AJim SchutzBob MillerNASDAQ: SNOAPage

Forward-Looking StatementExcept for historical information herein, matters set forth in this presentation are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “Company”).These forward-looking statements are identified by the use of words such as “believe,” “achieve,” and “strive,” among others. Forward-looking statements in this presentation are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, andother risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission. The Company disclaims any obligation to update these forward-looking statements, except as required by law.3NASDAQ: SNOAPage

Results from the Year Ending 31 Mar 2018

4Revenue = $16.7M +30% over FY 2017Gross U.S. dermatology revenue +85%Net U.S. dermatology revenue +40%International revenue +36%U.S. product revenue +27%Cash on Hand 3/31/18 = $10.1MNASDAQ: SNOAPage

Milestones Achieved in the year ended 31 Mar 2018þMarch 2018 –FDA approval to add antimicrobial indication to AcuicynþJanuary 2018 -Three UAE approvals for blepharitis, chronic rhinosinusitis and oral careþNov + Dec 2017 -Three FDA approvals to expand indications to add antimicrobial languageþOctober 2017 -Seven Brazilian dermatology approvals5þSeptember 2017 -Launched Loyon, indicated for scaling and erythema for various dermatosesþJune 2017 -Two Singapore dermatology approvalsþApril 2017 -Hired 13 additional sales reps, totaling 28 reps and 6 managersþApril 2017 -Two UAE dermatology approvalsþMarch 2017 -FDA approval for LoyonþMarch 2017 -Received $19.5M payment from LatAmpartner NASDAQ: SNOAPage